Chengdu Chipscreen Pharmaceutical patents new integrin αvβ1 and αvβ6 antagonists

April 23, 2025

Chengdu Chipscreen Pharmaceutical Ltd. has disclosed integrin αvβ1 and/or αvβ6 antagonists reported to be useful for the treatment of fibrosis.